Showing results (1501-1510 of 2,107) with videos related to
Sort By:
Pageof 211
CNS Drugs|October 13, 2018
From LBR-101 to Fremanezumab for MigraineMarcelo E Bigal, Alan M Rapoport, Stephen D Silberstein, et al.CNS Drugs|October 16, 2021
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future DirectionsJoshua T KantrowitzCNS Drugs|October 18, 2021
Tranexamic Acid for Adult Patients with Spontaneous Intracerebral Hemorrhage: A Systematic Review with Meta-analysisXing Wang, Lu Ma, Jinlei Song, et al.CNS Drugs|July 27, 2022
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity DisorderAzmi Nasser, Joseph T Hull, Soumya A Chaturvedi, et al.CNS Drugs|May 22, 2023
A Retrospective Real-Life Multicenter Study on Concurrent Oral Preventive Treatments in Patients with Chronic Migraine Treated with OnabotulinumtoxinALucas Hendrik Overeem, Raffaele Ornello, Maria Magdalena Pocora, et al.CNS Drugs|May 11, 2023
Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysisNevena V Radonjić, Alessio Bellato, Nayla M Khoury, et al.CNS Drugs|May 11, 2023
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental DisordersDicson S Malar, Premrutai Thitilertdecha, Kanokphorn S Ruckvongacheep, et al.CNS Drugs|May 8, 2023
Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple SclerosisTammy Jiang, Tjalf Ziemssen, Sibyl Wray, et al.CNS Drugs|April 27, 2021
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current StatusIoline D Henter, Lawrence T Park, Carlos A ZarateCNS Drugs|January 22, 2014
Clinical relevance of brain volume measures in multiple sclerosisNicola De Stefano, Laura Airas, Nikolaos Grigoriadis, et al.Pageof 211